Bruk av GnRH-antagonist ved in vitro-fertilisering

Tidsskrift for den Norske Laegeforening

Volumn 131, Issue 17, 2011, Pages 1649-1652

  Ekerhovd, Erling ^a,b  

^a Medicus   (Norway)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; DRUG DERIVATIVE; FOLLITROPIN; GANIRELIX; GONADORELIN; HORMONE ANTAGONIST;

ARTICLE; BLOOD; DRUG EFFECT; FEMALE; FERTILIZATION IN VITRO; FETUS ECHOGRAPHY; HUMAN; OVARY; OVULATION; PREGNANCY; PREGNANCY RATE; TREATMENT OUTCOME;

CHORIONIC GONADOTROPIN; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OVARY; OVULATION; PREGNANCY; PREGNANCY RATE; TREATMENT OUTCOME; ULTRASONOGRAPHY, PRENATAL;

EID: 80052767100     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.10.0489     Document Type: Article

References (47)

1. Land JA, Courtar DA, Evers JL. Patient dropout in an assisted reproductive technology program: implications for pregnancy rates. Fertil Steril 1997; 68: 278-81.
2. Schröder AK, Katalinic A, Diedrich K et al. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reprod Biomed Online 2004; 8: 600-6.
3. Olivius K, Friden B, Lundin K et al. Cumulative probability of live birth after three in vitro fertilization/ intracytoplasmic sperm injection cycles. Fertil Steril 2002; 77: 505-10.
4. Rajkhowa M, McConnell A, Thomas GE. Reasons for discontinuation of IVF treatment: a questionnaire study. Hum Reprod 2006; 21: 358-63.
5. Verberg MF, Eijkemans MJ, Heijnen EM et al. Why do couples drop-out from IVF treatment? A prospective cohort study. Hum Reprod 2008; 23: 2050-5.
6. Brandes M, van der Steen JO, Bokdam SB et al. When and why do subfertile couples discontinue their fertility care? A longitudinal cohort study in a secondary care subfertility population. Hum Reprod 2009; 24: 3127-35.
7. de Klerk C, Macklon NS, Heijnen EM et al. The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy. Hum Reprod 2007; 22: 2554-8.
8. Heijnen EM, Eijkemans MJ, De Klerk C et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007; 369: 743-9.
9. Pennings G, Ombelet W. Coming soon to your clinic: patient-friendly ART. Hum Reprod 2007; 22: 2075-9.
10. Devroey P, Aboulghar M, Garcia-Velasco J et al. Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009; 24: 764-74.
11. Huirne JA, Lambalk CB. Gonadotropin-releasinghormone-receptor antagonists. Lancet 2001; 358: 1793-803.
12. Kolibianakis EM, Albano C, Kahn J et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79: 873-80.
13. Lainas T, Zorzovilis J, Petsas G et al. In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF. Hum Reprod 2005; 20: 2426-33.
14. Devroey P, Boostanfar R, Koper NP et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; 24: 3063-72.
15. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online 2010; 21: 66-76.
16. Albano C, Felberbaum RE, Smitz J et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod 2000; 15: 526-31.
17. Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490-8.
18. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16: 644-51.
19. Fluker M, Grifo J, Leader A et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75: 38-45.
20. Nargund G, Fauser BC, Macklon NS et al. The ISMAAR proposal on terminology for ovarian stimulation for IVF. Hum Reprod 2007; 22: 2801-4.
21. Verberg MF, Macklon NS, Nargund G et al. Mild ovarian stimulation for IVF. Hum Reprod Update 2009; 15: 13-29.
22. Kolibianakis EM, Zikopoulos K, Smitz J et al. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 2004; 19: 1525-9.
23. Kolibianakis EM, Albano C, Kahn J et al. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropinreleasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003; 79: 873-80.
24. Kolibianakis EM, Zikopoulos K, Schiettecatte J et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004; 19: 2490-6.
25. Bosch E, Valencia I, Escudero E et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80: 1444-9.
26. Papanikolaou EG, Kolibianakis EM, Pozzobon C et al. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril 2009; 91: 949-52.
27. Bosch E, Vidal C, Labarta E et al. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists-a randomized study. Hum Reprod 2008; 23: 2346-51.
28. Marchini M, Fedele L, Bianchi S et al. Secretory changes in preovulatory endometrium during controlled ovarian hyperstimulation with buserelin acetate and human gonadotropins. Fertil Steril 1991; 55: 717-21.
29. Ubaldi F, Bourgain C, Tournaye H et al. Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase. Fertil Steril 1997; 67: 521-6.
30. Kolibianakis E, Bourgain C, Albano C et al. Effect of ovarian stimulation with recombinant folliclestimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002; 78: 1025-9.
31. Jacobs MH, Balasch J, Gonzalez-Merlo JM et al. Endometrial cytosolic and nuclear progesterone receptors in the luteal phase defect. J Clin Endocrinol Metab 1987; 64: 472-5.
32. Kolibianakis EM, Bourgain C, Papanikolaou EG et al. Prolongation of follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod 2005; 20: 2453-6.
33. Kolibianakis EM, Albano C, Camus M et al. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004; 82: 102-7.
34. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14: 640-9.
35. Kolibianakis EM, Collins J, Tarlatzis BC et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006; 12: 651-71.
36. Verberg MF, Eijkemans MJ, Macklon NS et al. The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update 2009; 15: 5-12.
37. Griesinger G, Kolibianakis EM, Venetis C et al. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropinreleasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010; 94: 2382-4.
38. Fanchin R, Salomon L, Castelo-Branco A et al. Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists. Hum Reprod 2003; 18: 2698-703.
39. Guivarc'h-Levêque A, Arvis P, Bouchet JL et al. Efficacité de la programmation des cycles FIV en antagonistes par les estrogènes. Gynecol Obstet Fertil 2010; 38: 18-22.
40. Fauser BC, Devroey P, Yen SS et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14: 2681-6.
41. Humaidan P, Kol S, Papanikolaou E. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011; 17: 510-24.
42. Ertzeid G, Storeng R. The impact of ovarian stimulation on implantation and fetal development in mice. Hum Reprod 2001; 16: 221-5.
43. Baart EB, Martini E, Eijkemans MJ et al. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007; 22: 980-8.
44. Xu YW, Peng YT, Wang B et al. High follicle-stimulating hormone increases aneuploidy in human oocytes matured in vitro. Fertil Steril 2011; 95: 99-104.
45. Wikland M, Bergh C, Borg K et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001; 16: 1676-81.
46. Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJ et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update 2011; 17: 184-96.
47. Nelson SM, Yates RW, Lyall H et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009; 24: 867-75.